Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies

Stefan Niewiesk, Stefan Niewiesk

Abstract

Neonates have an immature immune system, which cannot adequately protect against infectious diseases. Early in life, immune protection is accomplished by maternal antibodies transferred from mother to offspring. However, decaying maternal antibodies inhibit vaccination as is exemplified by the inhibition of seroconversion after measles vaccination. This phenomenon has been described in both human and veterinary medicine and is independent of the type of vaccine being used. This review will discuss the use of animal models for vaccine research. I will review clinical solutions for inhibition of vaccination by maternal antibodies, and the testing and development of potentially effective vaccines. These are based on new mechanistic insight about the inhibitory mechanism of maternal antibodies. Maternal antibodies inhibit the generation of antibodies whereas the T cell response is usually unaffected. B cell inhibition is mediated through a cross-link between B cell receptor (BCR) with the Fcγ-receptor IIB by a vaccine-antibody complex. In animal experiments, this inhibition can be partially overcome by injection of a vaccine-specific monoclonal IgM antibody. IgM stimulates the B cell directly through cross-linking the BCR via complement protein C3d and antigen to the complement receptor 2 (CR2) signaling complex. In addition, it was shown that interferon alpha binds to the CD21 chain of CR2 as well as the interferon receptor and that this dual receptor usage drives B cell responses in the presence of maternal antibodies. In lieu of immunizing the infant, the concept of maternal immunization as a strategy to protect neonates has been proposed. This approach would still not solve the question of how to immunize in the presence of maternal antibodies but would defer the time of infection to an age where infection might not have such a detrimental outcome as in neonates. I will review successful examples and potential challenges of implementing this concept.

Keywords: B cell receptor; FcγRIIB; cotton rat; maternal antibody; maternal immunization.

Figures

Figure 1
Figure 1
Model of B cell activation in the presence of maternal IgG. B cells are being stimulated through three signals, the first one is recognition of antigen by the B cell receptor (BCR), the second the interaction with T cells through CD40/CD40 ligand, and the third cytokines like type I interferon or IL-6. During vaccination in the presence of maternal antibodies T cell responses are generated and therefore the second signal is provided. (A) In the presence of maternal antibodies (IgG), the first signal is downregulated by a cross-link between BCR and FcγRIIB. If MV-specific IgG binds to MV, the constant region is bound by the receptor for the constant region (Fc) of IgG (which is FcγRIIB). FcγRIIB is the only Fc-receptor on B cells and does not bind other immunoglobulins like IgM or IgA. After juxtaposition of the BCR and FcγRIIB, the tyrosine-based inhibitory motif of FcγRIIB is in close proximity to the tyrosine-based activation motif of BCR and delivers a negative signal. (B) If MV-specific IgM binds to MV, it also binds via C3d to CD21 (complement receptor 2), which is part of the positively signaling CD21/CD19/CD83/Leu-13 complex. The opsonin C3d does not bind to IgG. (C) Interferon α (type I interferon) binds to both the interferon receptor and CD21, and the dual receptor usage leads to a strong positive signal. It stimulates antibody secretion by B cells in the presence of maternal antibodies. (D) A possible approach to vaccination in the presence of maternal antibodies is the reduction of the vaccine antigen into small units, which do form antigen–antibody complexes unable to cross-link BCR and FcγRIIB. An example of this approach is experimental vaccination against respiratory syncytial virus in the presence of maternal antibodies (138).

References

    1. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol (2009) 9:185–9410.1038/nri2508
    1. Butler JE, Lager KM, Splichal I, Francis D, Kacskovics I, Sinkora M, et al. The piglet as a model for B cell and immune system development. Vet Immunol Immunopathol (2009) 128:147–7010.1016/j.vetimm.2008.10.321
    1. Chattha KS, Firth MA, Hodgins DC, Shewen PE. Expression of complement receptor 2 (CD21), membrane IgM and the inhibitory receptor CD32 (FcgammaRIIb) in the lymphoid tissues of neonatal calves. Vet Immunol Immunopathol (2010) 137:99–10810.1016/j.vetimm.2010.04.016
    1. Chattha KS, Firth MA, Hodgins DC, Shewen PE. Variation in expression of membrane IgM, CD21 (CR2) and CD32 (Fcgamma RIIB) on bovine lymphocytes with age: a longitudinal study. Dev Comp Immunol (2010) 34:510–710.1016/j.dci.2009.12.010
    1. Morein B, Blomqvist G, Hu K. Immune responsiveness in the neonatal period. J Comp Pathol (2007) 137:S27–3110.1016/j.jcpa.2007.04.008
    1. Heiman HS, Weisman LE. Transplacental or enteral transfer of maternal immunization-induced antibody protects suckling rats from type III group B streptococcal infection. Pediatr Res (1989) 26:629–3210.1203/00006450-198912000-00023
    1. Svet-Moldavsky GJ, Svet-Moldasky IA. Sarcomas in cotton rats inoculated with Rous virus. Science (1964) 143:54–510.1126/science.143.3601.54
    1. Zepeda M, Wilson JM. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors. Gene Ther (1996) 3:973–9
    1. Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) (2006) 85:193–20210.1097/
    1. Ochola R, Sande C, Fegan G, Scott PD, Medley GF, Cane PA, et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One (2009) 4:e8088.10.1371/journal.pone.0008088
    1. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis (2010) 51:1355–6110.1086/657309
    1. Krakowka S, Long D, Koestner A. Influence of transplacentally acquired antibody on neonatal susceptibility to canine distemper virus in gnotobiotic dogs. J Infect Dis (1978) 137:605–810.1093/infdis/137.5.605
    1. Li X, Dong X, Sun X, Li W, Zhao P, Cui Z, et al. Preparation and immunoprotection of subgroup B avian leukosis virus inactivated vaccine. Vaccine (2013) 31:5479–8510.1016/j.vaccine.2013.08.072
    1. Leuridan E, Hens N, Hutse V, Aerts M, Van Damme P. Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine (2011) 29:2222–610.1016/j.vaccine.2010.06.004
    1. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine (2007) 25:6296–30410.1016/j.vaccine.2007.06.020
    1. Kilic A, Altinkaynak S, Ertekin V, Inandi T. The duration of maternal measles antibodies in children. J Trop Pediatr (2003) 49:302–510.1093/tropej/49.5.302
    1. Watanaveeradej V, Endy TP, Samakoses R, Kerdpanich A, Simasathien S, Polprasert N, et al. Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg (2003) 69:123–8
    1. Awa DN, Ngagnou A, Tefiang E, Yaya D, Njoya A. Post vaccination and colostral peste des petits ruminants antibody dynamics in research flocks of Kirdi goats and Foulbe sheep of north Cameroon. Prev Vet Med (2002) 55:265–7110.1016/S0167-5877(02)00013-2
    1. Tsutsui T, Yamamoto T, Hayama Y, Akiba Y, Nishiguchi A, Kobayashi S, et al. Duration of maternally derived antibodies against Akabane virus in calves: survival analysis. J Vet Med Sci (2009) 71:913–810.1292/jvms.71.913
    1. Winters WD, Clouse WJ, Harris SC. Concomitant transfer of BCG-CW and canine virus antibodies from dams to pups. Dev Comp Immunol (1981) 5:321–810.1016/0145-305X(81)90039-2
    1. Gharaibeh S, Mahmoud K. Decay of maternal antibodies in broiler chickens. Poult Sci (2013) 92:2333–610.3382/ps.2013-03249
    1. Epstein JH, Baker ML, Zambrana-Torrelio C, Middleton D, Barr JA, Dubovi E, et al. Duration of maternal antibodies against canine distemper virus and hendra virus in pteropid bats. PLoS One (2013) 8:e67584.10.1371/journal.pone.0067584
    1. Sohayati AR, Hassan L, Sharifah SH, Lazarus K, Zaini CM, Epstein JH, et al. Evidence for Nipah virus recrudescence and serological patterns of captive Pteropus vampyrus. Epidemiol Infect (2011) 139:1570–910.1017/S0950268811000550
    1. Baker KS, Suu-Ire R, Barr J, Hayman DTS, Broder CC, Horton DL, et al. Viral antibody dynamics in a chiropteran host. J Anim Ecol (2014) 83:415–2810.1111/1365-2656.12153
    1. Jones C, Pollock L, Barnett SM, Battersby A, Kampmann B. The relationship between concentration of specific antibody at birth and subsequent response to primary immunization. Vaccine (2014) 32:996–100210.1016/j.vaccine.2013.11.104
    1. Francis JP, Richmond PC, Pomat WS, Michael A, Keno H, Phuanukoonnon S, et al. Maternal antibodies to pneumolysin but not to pneumococcal surface protein a delay early pneumococcal carriage in high-risk Papua new Guinean infants. Clin Vaccine Immunol (2009) 16:1633–810.1128/CVI.00247-09
    1. Kurikka S, Kayhty H, Peltola H, Saarinen L, Eskola J, Makela PH. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatrics (1995) 95:815–22
    1. Englund JA, Anderson EL, Reed GF, Decker MD, Edwards KM, Pichichero ME, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics (1995) 96:580–4
    1. Whittle H, Hanlon P, O’Neil K, Hanlon L, Marsh V, Jupp E. Trial of high-dose Edmonston-Zagreb measles vaccine in Gambia: antibody response and side-effects. Lancet (1988) 2:811–410.1016/S0140-6736(88)92781-X
    1. Garly ML, Bale C, Martins CL, Monteiro M, George E, Kidd M, et al. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine (2001) 19:1951–910.1016/S0264-410X(00)00431-X
    1. Borras E, Urbiztondo L, Costa J, Batalla J, Torner N, Plasencia A, et al. Measles antibodies and response to vaccination in children aged less than 14 months: implications for age of vaccination. Epidemiol Infect (2012) 140:1599–60610.1017/S0950268811002184
    1. Gans H, Dehovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine (2003) 21:3398–40510.1016/S0264-410X(03)00341-4
    1. Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, Krause DS, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr (2004) 144:327–3210.1016/j.jpeds.2003.11.030
    1. Hu Y, Wu Q, Xu B, Zhou Z, Wang Z, Zhou YH. Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine (2008) 26:6064–710.1016/j.vaccine.2008.09.014
    1. Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, et al. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine (2014) 32:651–610.1016/j.vaccine.2013.12.017
    1. Sormunen H, Stenvik M, Eskola J, Hovi T. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol (2001) 63:305–1010.1002/1096-9071(200104)63:4<305::AID-JMV1006>;2-U
    1. Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child (1985) 139:977–80
    1. Warren RJ, Lepow ML, Bartsch GE, Robbins FC. The relationship of maternal antibody. Pediatrics (1964) 34:4–13
    1. Piedra PA, Glezen WP, Mbawuike I, Gruber WC, Baxter BD, Boland FJ, et al. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine (1993) 11:718–2410.1016/0264-410X(93)90255-V
    1. Pollock RV, Carmichael LE. Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J Am Vet Med Assoc (1982) 180:37–42
    1. Waner T, Naveh A, Wudovsky I, Carmichael LE. Assessment of maternal antibody decay and response to canine parvovirus vaccination using a clinic-based enzyme-linked immunosorbent assay. J Vet Diagn Invest (1996) 8:427–3210.1177/104063879600800404
    1. Iida H, Fukuda S, Kawashima N, Yamazaki T, Aoki J, Tokita K, et al. [Effect of maternally derived antibody levels on antibody responses to canine parvovirus, canine distemper virus and infectious canine hepatitis virus after vaccinations in beagle puppies] article in Japanese. Jikken Dobutsu (1990) 39:9–19
    1. Chappuis G. Control of canine distemper. Vet Microbiol (1995) 44:351–810.1016/0378-1135(95)00028-9
    1. Digangi BA, Levy JK, Griffin B, Reese MJ, Dingman PA, Tucker SJ, et al. Effects of maternally-derived antibodies on serologic responses to vaccination in kittens. J Feline Med Surg (2012) 14:118–2310.1177/1098612X11432239
    1. Jakel V, Cussler K, Hanschmann KM, Truyen U, Konig M, Kamphuis E, et al. Vaccination against Feline Panleukopenia: implications from a field study in kittens. BMC Vet Res (2012) 8:62.10.1186/1746-6148-8-62
    1. Downey ED, Tait RG, Jr, Mayes MS, Park CA, Ridpath JF, Garrick DJ, et al. An evaluation of circulating bovine viral diarrhea virus type 2 maternal antibody level and response to vaccination in Angus calves. J Anim Sci (2013) 91:4440–5010.2527/jas.2012-5890
    1. Endsley JJ, Roth JA, Ridpath J, Neill J. Maternal antibody blocks humoral but not T cell responses to BVDV. Biologicals (2003) 31:123–510.1016/S1045-1056(03)00027-7
    1. Patil PK, Sajjanar CM, Natarajan C, Bayry J. Neutralizing antibody responses to foot-and-mouth disease quadrivalent (type O, A, C and Asia 1) vaccines in growing calves with pre-existing maternal antibodies. Vet Microbiol (2014) 169(3–4):233–510.1016/j.vetmic.2014.01.005
    1. Ellis JA, Gow SP, Goji N. Response to experimentally induced infection with bovine respiratory syncytial virus following intranasal vaccination of seropositive and seronegative calves. J Am Vet Med Assoc (2010) 236:991–910.2460/javma.236.9.991
    1. Ellis JA, Gow SP, Mahan S, Leyh R. Duration of immunity to experimental infection with bovine respiratory syncytial virus following intranasal vaccination of young passively immune calves. J Am Vet Med Assoc (2013) 243:1602–810.2460/javma.243.11.1602
    1. van der Sluijs MT, Kuhn EM, Makoschey B. A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody. BMC Vet Res (2010) 11(6):2.10.1186/1746-6148-6-2
    1. Pomorska-Mol M, Markowska-Daniel I, Pejsak Z. Effect of age and maternally-derived antibody status on humoral and cellular immune responses to vaccination of pigs against Erysipelothrix rhusiopathiae. Vet J (2012) 194:128–3010.1016/j.tvjl.2012.03.009
    1. Pomorska-Mol M, Markowska-Daniel I, Pejsak Z. Evaluation of humoral and antigen-specific T-cell responses after vaccination of pigs against pseudorabies in the presence of maternal antibodies. Vet Microbiol (2010) 144:450–410.1016/j.vetmic.2010.01.015
    1. Klinkenberg D, Moormann RJ, De Smit AJ, Bouma A, De Jong MC. Influence of maternal antibodies on efficacy of a subunit vaccine: transmission of classical swine fever virus between pigs vaccinated at 2 weeks of age. Vaccine (2002) 20:3005–1310.1016/S0042-207X(02)00283-X
    1. Suradhat S, Damrongwatanapokin S. The influence of maternal immunity on the efficacy of a classical swine fever vaccine against classical swine fever virus, genogroup 2.2, infection. Vet Microbiol (2003) 92:187–9410.1016/S0378-1135(02)00357-7
    1. Markowska-Daniel I, Pomorska-Mol M, Pejsak Z. The influence of age and maternal antibodies on the postvaccinal response against swine influenza viruses in pigs. Vet Immunol Immunopathol (2011) 142:81–610.1016/j.vetimm.2011.03.019
    1. Forrest HL, Garcia A, Danner A, Seiler JP, Friedman K, Webster RG, et al. Effect of passive immunization on immunogenicity and protective efficacy of vaccination against a Mexican low-pathogenic avian H5N2 influenza virus. Influenza Other Respir Viruses (2013) 7:1194–20110.1111/irv.12140
    1. Fry TL, Vandalen KK, Shriner SA, Moore SM, Hanlon CA, Vercauteren KC. Humoral immune response to oral rabies vaccination in raccoon kits: problems and implications. Vaccine (2013) 31:2811–510.1016/j.vaccine.2013.04.016
    1. Pare JA, Barker IK, Crawshaw GJ, Mcewen SA, Carman PS, Johnson RP. Humoral response and protection from experimental challenge following vaccination of raccoon pups with a modified-live canine distemper virus vaccine. J Wildl Dis (1999) 35:430–910.7589/0090-3558-35.3.430
    1. Maia OB, Gouveia AM. Serologic response of maned wolves (Chrysocyon brachyurus) to canine distemper virus and canine parvovirus vaccination. J Zoo Wildl Med (2001) 32:78–80
    1. Welter J, Taylor J, Tartaglia J, Paoletti E, Stephensen CB. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. J Virol (2000) 74:6358–6710.1128/JVI.74.14.6358-6367.2000
    1. Katz SL, John F. Enders and measles virus vaccine–a reminiscence. Curr Top Microbiol Immunol (2009) 329:3–11
    1. Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA. Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol (2001) 75:910–2010.1128/JVI.75.2.910-920.2001
    1. Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine (2008) 26:383–9810.1016/j.vaccine.2007.11.010
    1. Griffin DE, Pan C-H. Measles: old vaccines and new vaccines. In: Griffin DE, Oldstone MBA, editors. Measles – Pathogenesis and Control. Heidelberg: Springer Verlag; (2009). p. 191–212
    1. Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J Infect Dis (1994) 170(Suppl 1):S24–3110.1093/infdis/170.Supplement_1.S24
    1. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, et al. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol (2003) 77:4396–40010.1128/JVI.77.7.4396-4400.2003
    1. Pueschel K, Tietz A, Carsillo M, Steward M, Niewiesk S. Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance. J Virol (2007) 81:8571–810.1128/JVI.00160-07
    1. Finke D, Liebert UG. CD4+ T cells are essential in overcoming experimental murine measles encephalitis. Immunology (1994) 83:184–9
    1. Weidinger G, Henning G, Ter Meulen V, Niewiesk S. Inhibition of major histocompatibility complex class II-dependent antigen presentation by neutralization of gamma interferon leads to breakdown of resistance against measles virus-induced encephalitis. J Virol (2001) 75:3059–6510.1128/JVI.75.7.3059-3065.2001
    1. McNulty J, Nair JJ, Griffin C, Pandey S. synthesis and biological evaluation of fully functionalized seco-pancratistatin analogues. J Nat Prod (2008) 71:357–6310.1021/np0705460
    1. Aaby P, Martins CL, Garly ML, Andersen A, Fisker AB, Claesson MH, et al. Measles vaccination in the presence or absence of maternal measles antibody: impact on child survival. Clin Infect Dis (2014) 59(4):484–9210.1093/cid/ciu354
    1. Samb B, Aaby P, Whittle HC, Seck AM, Rahman S, Bennett J, et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J (1995) 14:203–910.1097/00006454-199503000-00007
    1. Gans H, Yasukawa L, Rinki M, Dehovitz R, Forghani B, Beeler J, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis (2001) 184:817–2610.1086/323346
    1. Gans HA, Yasukawa LL, Alderson A, Rinki M, Dehovitz R, Beeler J, et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis (2004) 190:83–9010.1086/421032
    1. Njie-Jobe J, Nyamweya S, Miles DJ, Van Der Sande M, Zaman S, Touray E, et al. Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. Vaccine (2012) 30:2543–5010.1016/j.vaccine.2012.01.083
    1. Bertley FM, Ibrahim SA, Libman M, Ward BJ. Measles vaccination in the presence of maternal antibodies primes for a balanced humoral and cellular response to revaccination. Vaccine (2004) 23:444–910.1016/j.vaccine.2004.06.021
    1. Aaby P, Jensen T, Hansen H. Trial of high dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet (1988) 2:809–1110.1016/S0140-6736(88)92780-8
    1. Garenne M, Leroy O, Beau J, Sene I. Child mortality after high titer measles vaccine: prospective study in Senegal. Lancet (1991) 338:903–710.1016/0140-6736(91)91771-L
    1. Halsey N. Increased mortality following high titer measles vaccines: too much good thing. Pediatr Infect Dis J (1993) 12:462–510.1097/00006454-199306000-00002
    1. Seng R, Samb B, Simondon F, Cisse B, Soumare M, Jensen H, et al. Increased long term mortality associated with rash after early measles vaccination in rural Senegal. Pediatr Infect Dis J (1999) 18:48–5210.1097/00006454-199901000-00012
    1. Martins C, Bale C, Garly ML, Rodrigues A, Lisse IM, Andersen A, et al. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination. Vaccine (2009) 27:5220–510.1016/j.vaccine.2009.06.076
    1. Techasena W, Sriprasert P, Pattamadilok S, Wongwacharapipoon P. Measles antibody in mothers and infants 0-2 years and response to measles vaccine at the age of 9 and 18 months. J Med Assoc Thai (2007) 90:106–12
    1. Gans HA, Arvin AM, Galinus J, Logan L, Dehovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 280:527–3210.1001/jama.280.6.527
    1. Johnson CE, Darbari A, Darbari DS, Nalin D, Whitwell J, Chui LW, et al. Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month old infants. Vaccine (2000) 18:2411–510.1016/S0264-410X(99)00574-5
    1. Martins CL, Garly ML, Bale C, Rodrigues A, Ravn H, Whittle HC, et al. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. Br Med J (2008) 337:a661.10.1136/bmj.a661
    1. Gagneur A, Pinquier D, Aubert M, Balu L, Brissaud O, De Pontual L, et al. Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006. Clin Vaccine Immunol (2008) 15:1845–5010.1128/CVI.00229-08
    1. Oyedele OO, Odemuyiwa SO, Ammerlaan W, Muller CP, Adu FD. Passive immunity to measles in the breastmilk and cord blood of some nigerian subjects. J Trop Pediatr (2005) 51:45–810.1093/tropej/fmh073
    1. Szenborn L, Tischer A, Pejcz J, Rudkowski Z, Wojcik M. Passive acquired immunity against measles in infants born to naturally infected and vaccinated mothers. Med Sci Monit (2003) 9:CR541–6.
    1. Pomorska-Mol M, Markowska-Daniel I. Interferon-gamma secretion and proliferative responses of peripheral blood mononuclear cells after vaccination of pigs against Aujeszky’s disease in the presence of maternal immunity. FEMS Immunol Med Microbiol (2010) 58:405–1110.1111/j.1574-695X.2010.00651.x
    1. Rodewald R, Kraehenbuhl JP. Receptor-mediated transport of IgG. J Cell Biol (1984) 99:159s–64s10.1083/jcb.99.1.159s
    1. Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature (1989) 337:184–710.1038/337184a0
    1. Costa-Carvalho BT, Vieria HM, Dimantas RB, Arslanian C, Naspitz CK, Sole D, et al. Transfer of IgG subclasses across placenta in term and preterm newborns. Braz J Med Biol Res (1996) 29:201–4
    1. Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients (2011) 3(4):442–7410.3390/nu3040442
    1. Rodewald R. Selective antibody transport in the proximal small intestine of the neonatal rat. J Cell Biol (1970) 45:635–4010.1083/jcb.45.3.635
    1. Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest (1972) 51:2916–2710.1172/JCI107116
    1. Rodewald R. Intestinal transport of antibodies in the newborn rat. J Cell Biol (1973) 58:189–21110.1083/jcb.58.1.189
    1. Rodewald R. Distribution of immunoglobulin G receptors in the small intestine of the young rat. J Cell Biol (1980) 85:18–3210.1083/jcb.85.1.18
    1. Favaron PO, Carter AM, Ambrosio CE, Morini AC, Mess AM, De Oliveira MF, et al. Placentation in Sigmodontinae: a rodent taxon native to South America. Reprod Biol Endocrinol (2011) 9:55.10.1186/1477-7827-9-55
    1. Prince GA, Horswood RL, Camargo E, Koenig D, Chanock RM. Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun (1983) 42:81–7
    1. Winters WD. Time dependent decreases of maternal canine virus antibodies in newborn pups. Vet Rec (1981) 108:295–910.1136/vr.108.14.295
    1. Omata Y, Oikawa H, Kanda M, Mikazuki K, Dilorenzo C, Claveria FG, et al. Transfer of antibodies to kittens from mother cats chronically infected with Toxoplasma gondii. Vet Parasitol (1994) 52:211–810.1016/0304-4017(94)90113-9
    1. Casal ML, Jezyk PF, Giger U. Transfer of colostral antibodies from queens to their kittens. Am J Vet Res (1996) 57:1653–8
    1. Claus MA, Levy JK, Macdonald K, Tucker SJ, Crawford PC. Immunoglobulin concentrations in feline colostrum and milk, and the requirement of colostrum for passive transfer of immunity to neonatal kittens. J Feline Med Surg (2006) 8:184–9110.1016/j.jfms.2006.01.001
    1. Bourne FJ, Curtis J. The transfer of immunoglobins IgG, IgA and IgM from serum to colostrum and milk in the sow. Immunology (1973) 24:157–62
    1. Stirling CM, Charleston B, Takamatsu H, Claypool S, Lencer W, Blumberg RS, et al. Characterization of the porcine neonatal Fc receptor – potential use for trans-epithelial protein delivery. Immunology (2005) 114:542–5310.1111/j.1365-2567.2004.02121.x
    1. Cervenak J, Kacskovics I. The neonatal Fc receptor plays a crucial role in the metabolism of IgG in livestock animals. Vet Immunol Immunopathol (2009) 128:171–710.1016/j.vetimm.2008.10.300
    1. Cutting JA, Roth TF. Changes in specific sequestration of protein during transport into the developing oocyte of the chicken. Biochim Biophys Acta (1973) 298:951–510.1016/0005-2736(73)90398-2
    1. West AP, Jr, Herr AB, Bjorkman PJ. The chicken yolk sac IgY receptor, a functional equivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2 receptor homolog. Immunity (2004) 20:601–1010.1016/S1074-7613(04)00113-X
    1. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol (2012) 2012:985646.10.1155/2012/985646
    1. Staley TE, Bush LJ. Receptor mechanisms of the neonatal intestine and their relationship to immunoglobulin absorption and disease. J Dairy Sci (1985) 68:184–20510.3168/jds.S0022-0302(85)80812-2
    1. Lecce JG, Morgan DO. Effect of dietary regimen on cessation of intestinal absorption of large molecules (closure) in the neonatal pig and lamb. J Nutr (1962) 78:263–8
    1. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol (2001) 13:1551–910.1093/intimm/13.12.1551
    1. Kim D, Huey D, Oglesbee M, Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood (2011) 117:6143–5110.1182/blood-2010-11-320317
    1. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113:3716–2510.1182/blood-2008-09-179754
    1. Willcocks LC, Smith KG, Clatworthy MR. Low-affinity Fcgamma receptors, autoimmunity and infection. Expert Rev Mol Med (2009) 11:e24.10.1017/S1462399409001161
    1. Prince GA, Horswood RL, Camargo E, Suffin SC, Chanock RM. Parenteral immunization with live respiratory syncytial virus is blocked in seropositive cotton rats. Infect Immun (1982) 37:1074–8
    1. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol (1988) 62:3907–10
    1. De Groot AS, Moise L, Mcmurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood (2008) 112:3303–1110.1182/blood-2008-02-138073
    1. Bruggemann M, Rajewsky K. Regulation of the antibody response against hapten-coupled erythrocytes by monoclonal antihapten antibodies of various isotypes. Cell Immunol (1982) 71:365–7310.1016/0008-8749(82)90270-2
    1. Heyman B, Wigzell H. Immunoregulation by monoclonal sheep erythrocyte-specific IgG antibodies: suppression is correlated to level of antigen binding and not to isotype. J Immunol (1984) 132:1136–43
    1. Karlsson MC, Wernersson S, Diaz , De Stahl T, Gustavsson S, Heyman B. Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. Proc Natl Acad Sci U S A (1999) 96:2244–910.1073/pnas.96.5.2244
    1. Getahun A, Heyman B. Studies on the mechanism by which antigen-specific IgG suppresses primary antibody responses: evidence for epitope masking and decreased localization of antigen in the spleen. Scand J Immunol (2009) 70:277–8710.1111/j.1365-3083.2009.02298.x
    1. Karlsson MC, Getahun A, Heyman B. FcgammaRIIB in IgG-mediated suppression of antibody responses: different impact in vivo and in vitro. J Immunol (2001) 167:5558–6410.4049/jimmunol.167.10.5558
    1. Heyman B, Pilstrom L, Shulman MJ. Complement activation is required for IgM-mediated enhancement of the antibody response. J Exp Med (1988) 167:1999–200410.1084/jem.167.6.1999
    1. Heyman B, Nose M, Weigle WO. Carbohydrate chains on IgG2b: a requirement for efficient feedback immunosuppression. J Immunol (1985) 134:4018–23
    1. Sinclair NR, Lees RK, Elliott EV. Role of the Fc fragment in the regulation of the primary immune response. Nature (1968) 220:1048–910.1038/2201048a0
    1. Sinclair NR. Regulation of the immune response. J Exp Med (1969) 129:1183–20110.1084/jem.129.6.1183
    1. Lyubchenko T, Dal Porto J, Cambier JC, Holers VM. Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J Immunol (2005) 174:3264–7210.4049/jimmunol.174.6.3264
    1. Thornton BP, Vetvicka V, Ross GD. Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells. Clin Exp Immunol (1996) 104:531–7
    1. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol (2000) 18:393–42210.1146/annurev.immunol.18.1.393
    1. Applequist SE, Dahlstrom J, Jiang N, Molina H, Heyman B. Antibody production in mice deficient for complement receptors 1 and 2 can be induced by IgG/Ag and IgE/Ag, but not IgM/Ag complexes. J Immunol (2000) 165:2398–40310.4049/jimmunol.165.5.2398
    1. Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J Immunol (2002) 168:3691–70110.4049/jimmunol.168.8.3697
    1. Schlereth B, Buonocore L, Tietz A, Ter Meulen V, Rose JK, Niewiesk S. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol (2003) 84:2145–5110.1099/vir.0.19050-0
    1. Weidinger G, Ohlmann M, Schlereth B, Sutter G, Niewiesk S. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine (2001) 19:2764–810.1016/S0264-410X(00)00531-4
    1. Schlereth B, Germann PG, ter Meulen V, Niewiesk S. DNA vaccination with the hemagglutinin and the fusion proteins, but not the nucleocapsid protein protects against experimental measles virus infection. J Gen Virol (2000) 81:1321–5
    1. Kim D, Niewiesk S. Synergistic induction of interferon alpha through TLR-3 and TLR-9 agonists identifies CD21 as interferon alpha receptor for the B Cell response. PLoS Pathog (2013) 9:e1003233.10.1371/journal.ppat.1003233
    1. Siegrist C-A, Plotnicky-Gilquin H, Cordova M, Berney M, Bonnefoy J-Y, Nguyen TN, et al. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J Infect Dis (1999) 179:1326–3310.1086/314778
    1. Delcayre AX, Salas F, Mathur S, Kovats K, Lotz M, Lernhardt W. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. EMBO J (1991) 10:919–26
    1. Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, et al. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J Immunol (2006) 177:383–9410.4049/jimmunol.177.1.383
    1. Kim D, Niewiesk S. Synergistic induction of interferon a through TLR-3 and TLR-9 agonists stimulates immune responses against measles virus in neonatal cotton rats. Vaccine (2014) 32(2):265–7010.1016/j.vaccine.2013.11.013
    1. Niewiesk S. Current animal models: cotton rat. In: Griffin DE, Oldstone MBA, editors. Measles – Pathogenesis and Control. Heidelberg: Springer Verlag; (2009). p. 89–110
    1. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 8:34–4710.1038/nri2206
    1. Enriquez-Rincon F, Klaus GG. Differing effects of monoclonal anti-hapten antibodies on humoral responses to soluble or particulate antigens. Immunology (1984) 52:129–36
    1. Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron (1999) 30:597–62310.1016/S0968-4328(99)00036-0
    1. Daikoku E, Morita C, Kohno T, Sano K. Analysis of morphology and infectivity of measles virus particles. Bull Osaka Med Coll (2007) 53:107–14
    1. Bouche FB, Ertl OT, Muller CP. Neutralizing B cell responses in measles. Viral Immunol (2002) 15:451–7210.1089/088282402760312331
    1. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun (1997) 65:1387–94
    1. Yoshida M, Masuda A, Kuo TT, Kobayashi K, Claypool SM, Takagawa T, et al. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin Immunopathol (2006) 28:397–40310.1007/s00281-006-0054-z
    1. Vincent AL, Ma W, Lager KM, Richt JA, Janke BH, Sandbulte MR, et al. Live attenuated influenza vaccine provides superior protection from heterologous infection in pigs with maternal antibodies without inducing vaccine-associated enhanced respiratory disease. J Virol (2012) 86:10597–60510.1128/JVI.01439-12
    1. Sarfati-Mizrahi D, Lozano-Dubernard B, Soto-Priante E, Castro-Peralta F, Flores-Castro R, Loza-Rubio E, et al. Protective dose of a recombinant Newcastle disease LaSota-avian influenza virus H5 vaccine against H5N2 highly pathogenic avian influenza virus and velogenic viscerotropic Newcastle disease virus in broilers with high maternal antibody levels. Avian Dis (2010) 54:239–4110.1637/8735-032509-Reg.1
    1. Blasco E, Lambot M, Barrat J, Cliquet F, Brochier B, Renders C, et al. Kinetics of humoral immune response after rabies VR-G oral vaccination of captive fox cubs (Vulpes vulpes) with or without maternally derived antibodies against the vaccine. Vaccine (2001) 19:4805–1510.1016/S0264-410X(01)00211-0
    1. Zhou X, Wang D, Xiong J, Zhang P, Li Y, She R. Protection of chickens, with or without maternal antibodies, against IBDV infection by a recombinant IBDV-VP2 protein. Vaccine (2010) 28:3990–610.1016/j.vaccine.2010.03.021
    1. Polewicz M, Gracia A, Garlapati S, Van Kessel J, Strom S, Halperin SA, et al. Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies. Vaccine (2013) 31:3148–5510.1016/j.vaccine.2013.05.008
    1. Schofield FD, Tucker VM, Westbrook GR. Neonatal tetanus in New Guinea. Br Med J (1961) 2:785–910.1136/bmj.2.5255.785
    1. WHO. Maternal and Neonatal Tetanus (MNT) elimination [Online]. (2014). Available from:
    1. Wutzler P, Schmidt-Ott R, Hoyer H, Sauerbrei A. Prevalence of influenza A and B antibodies in pregnant women and their offspring. J Clin Virol (2009) 46:161–410.1016/j.jcv.2009.06.024
    1. Rohner GB, Meier S, Bel M, Combescure C, Othenin-Girard V, Swali RA, et al. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn. Pediatr Infect Dis J (2013) 32:1374–8010.1097/01.inf.0000437066.40840.c4
    1. Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med (2011) 165:104–1110.1001/archpediatrics.2010.192
    1. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med (2008) 359:1555–6410.1056/NEJMoa0708630
    1. Cohen P, Scadron SJ. The effects of active immunization of the mother upon the offspring. J Pediatr (1946) 29:609–1910.1016/S0022-3476(46)80128-8
    1. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol (2011) 204(334):e331–510.1016/j.ajog.2010.11.024
    1. Leuridan E, Hens N, Peeters N, De Witte L, Van Der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J (2011) 30:608–1010.1097/INF.0b013e3182093814
    1. Westra TA, De Vries R, Tamminga JJ, Sauboin CJ, Postma MJ. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther (2010) 32:1479–9510.1016/j.clinthera.2010.07.017
    1. Lopes CR, Berezin EN, Ching TH, Canuto Jde S, Costa VO, Klering EM. Ineffectiveness for infants of immunization of mothers with pneumococcal capsular polysaccharide vaccine during pregnancy. Braz J Infect Dis (2009) 13: 104–6
    1. Michaux JL, Heremans JF, Hitzig WH. Immunoglobulin levels in cord-blood serum of negroes and caucasians. Trop Geogr Med (1966) 18:10–4
    1. Saji F, Koyama M, Matsuzaki N. Current topic: human placental Fc receptors. Placenta (1994) 15:453–6610.1016/S0143-4004(05)80415-1
    1. Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod (1999) 4:81–910.1530/ror.0.0040081
    1. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol (1996) 36:248–5510.1111/j.1600-0897.1996.tb00172.x
    1. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis (2013) 56:539–4410.1093/cid/cis923
    1. Cavalcante RS, Kopelman BI, Costa-Carvalho BT. Placental transfer of Haemophilus influenzae type b antibodies in malnourished pregnant women. Braz J Infect Dis (2008) 12:47–5110.1590/S1413-86702008000100011
    1. Doroudchi M, Samsami Dehaghani A, Emad K, Ghaderi A. Placental transfer of rubella-specific IgG in fullterm and preterm newborns. Int J Gynaecol Obstet (2003) 81:157–6210.1016/S0020-7292(02)00442-3
    1. Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert Rev Vaccines (2008) 7:249–5810.1586/14760584.7.2.249
    1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet (2010) 375:1545–5510.1016/S0140-6736(10)60206-1
    1. Roca A, Abacassamo F, Loscertales MP, Quinto L, Gomez-Olive X, Fenwick F, et al. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol (2002) 67:616–2310.1002/jmv.10148
    1. Kaaijk P, Luytjes W, Rots NY. Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Hum Vaccin Immunother (2013) 9:1263–710.4161/hv.24096
    1. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 176:1215–2410.1086/514115
    1. Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol (2005) 350:126–4410.1016/j.jmb.2005.04.049
    1. Widjojoatmodjo MN, Boes J, Van Bers M, Van Remmerden Y, Roholl PJ, Luytjes W. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J (2010) 7:114.10.1186/1743-422X-7-114
    1. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 342:592–810.1126/science.1243283
    1. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 340:1113–710.1126/science.1234914
    1. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature (2013) 501:439–4310.1038/nature12442
    1. Murphy BR, Alling DW, Snyder MH, Walsh EE, Prince GA, Chanock RM, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol (1986) 24:894–8
    1. Shinoff JJ, O’brien KL, Thumar B, Shaw JB, Reid R, Hua W, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis (2008) 198:1007–1510.1086/591460

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere